Human CLDN18-A2-GFP Virus-Like Particles

Human CLDN18-A2-GFP Virus-Like Particles (VLPs) are sophisticated nanostructures engineered to display the full-length human Claudin 18.2 protein in its native, multi-pass transmembrane state. Since Claudin 18.2 is a highly hydrophobic four-pass membrane protein, it is notoriously challenging to extract and stabilize in a functional form using conventional detergent-based purification methods. These VLPs solve this issue by utilizing the self-assembly properties of viral capsid proteins to bud from host cell membranes, effectively capturing the CLDN18.2 protein within a lipid bilayer that mimics a natural cellular environment. The inclusion of a Green Fluorescent Protein (GFP) fusion tag acts as a versatile reporter, enabling direct visualization and quantification of the particles. By maintaining the correct quaternary structure and high-density presentation of extracellular loops, these VLPs provide an authentic representation of the target as it would appear on the surface of a tumor cell.

The applications of CLDN18-A2-GFP VLPs are extensive within the development of targeted cancer therapeutics, particularly for gastric and pancreatic malignancies. They are frequently employed as high-quality antigens in the discovery and characterization of monoclonal antibodies, as well as in the screening of bispecific antibodies and antibody-drug conjugates (ADCs). The built-in GFP signal makes these particles particularly useful for flow cytometry-based binding assays, allowing researchers to evaluate the specificity and affinity of lead candidates without the need for secondary labeling. These particles also serve as robust reagents for validating CAR-T cell activation and for use in ligand-receptor interaction studies via Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI). By providing a stable, high-concentration format of a difficult-to-express clinical target, these VLPs significantly streamline the workflow for identifying and optimizing next-generation immuno-oncology drugs.